Pfizer PFE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $63.32B+1.2% | $62.58B-0.3% | $62.79B-1.6% | $63.83B+2.2% | $62.46B-1.8% | ||
| $16.77B+4.4% | $16.07B-3.8% | $16.7B-6.1% | $17.8B+2.8% | $17.32B-3.0% | ||
| $46.55B+0.1% | $46.51B+0.9% | $46.08B+0.1% | $46.04B+2.0% | $45.15B-1.4% | ||
| 73.5%-0.8pp | 74.3%+0.9pp | 73.4%+1.3pp | 72.1%-0.2pp | 72.3%+0.3pp | ||
| $13.72B-0.5% | $13.79B-0.8% | $13.91B-0.4% | $13.96B-2.1% | $14.27B-3.2% | ||
| $5.28B+8.2% | $4.88B-2.6% | $5B-1.7% | $5.09B-1.9% | $5.19B-9.2% | ||
| —— | —— | $9.16B-13.1% | $10.54B+42.5% | $7.4B-7.9% | ||
| $384M+244% | -$266M+61.2% | -$685M-191% | -$235M+53.9% | -$510M-1,721% | ||
| —— | —— | $9.83B-8.6% | $10.75B+36.4% | $7.88B-1.8% | ||
| $12M-52.0% | $25M-21.9% | $32M+33.3% | $24M+50.0% | $16M+45.5% | ||
| —— | —— | $1.72-8.5% | $1.88+36.2% | $1.38-2.1% | ||
| —— | —— | $1.72-9.0% | $1.89+36.0% | $1.39-2.1% | ||
| 22.9B+0.1% | 22.8B+0.1% | 22.8B0.0% | 22.8B0.0% | 22.8B+0.1% | ||
| 22.7B+0.1% | 22.7B+0.1% | 22.7B+0.1% | 22.7B+0.1% | 22.7B+0.1% | ||
| $9.49B+2.4% | $9.27B+3.7% | $8.93B+4.7% | $8.53B+2.5% | $8.33B-0.7% | ||
| $4.85B-0.6% | $4.88B-2.6% | $5B-1.7% | $5.09B-1.9% | $5.19B-1.8% | ||
| $973M-37.3% | $1.55B-8.5% | $1.7B-1.6% | $1.72B-42.5% | $3B+23.8% | ||
| $4.61B-1.7% | $4.69B+14.2% | $4.1B-7.0% | $4.41B+23.5% | $3.57B-0.9% | ||
| —— | —— | $1.72-9.0% | $1.89+36.0% | $1.39-2.1% | ||
| —— | —— | $1.72-9.0% | $1.89+36.0% | $1.39-2.1% | ||
| $0.00— | $0.00— | $0.00— | $0.00— | $0.00— | ||
| -$1.48B+30.5% | -$2.13B-1.8% | -$2.1B-15.6% | -$1.81B+22.0% | -$2.32B-10.6% | ||
| $4.61B-1.7% | $4.69B+14.2% | $4.1B-7.0% | $4.41B+23.5% | $3.57B-0.9% | ||
| $2.68B-2.2% | $2.74B-13.1% | $3.15B-0.2% | $3.16B-0.3% | $3.17B-1.9% | ||
| —— | —— | —— | —— | $219M+23.0% | ||
| -$8.53B+21.8% | -$10.9B+31.9% | -$16.01B+11.9% | -$18.17B-4.2% | -$17.44B-1.7% | ||
| -$3.84B-184% | -$1.35B— | —— | —— | —— | ||
| $12.57B+2.3% | $12.29B-10.1% | $13.66B-13.4% | $15.77B+12.7% | $13.99B+9.8% | ||
| $603M+28.3% | $470M-78.2% | $2.16B-16.4% | $2.58B+24.7% | $2.07B-8.5% | ||
| -$6.63B+1.4% | -$6.72B-47.2% | -$4.57B-6.4% | -$4.29B+7.9% | -$4.66B-6.2% | ||
| —— | —— | —— | —— | -$302M-15,000% | ||
| —— | —— | —— | —— | —— | ||
| $2.5B-4.9% | $2.63B-2.7% | $2.7B-1.8% | $2.75B-0.7% | $2.77B-4.8% | ||
| $14.1B-1.8% | $14.36B-12.9% | $16.48B+10.2% | $14.96B+23.1% | $12.16B+20.0% | ||
| -$386M+15.7% | -$458M-6.8% | -$429M-8.1% | -$397M+9.6% | -$439M+6.4% | ||
| —— | —— | —— | —— | —— | ||
| $1.1B+0.5% | $1.1B+105% | $533M-62.0% | $1.4B+4.2% | $1.35B-14.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $8.57B-33.8% | $12.95B+15.3% | ||
| $10.72B+2.7% | $10.44B+1.7% | $10.27B-0.5% | $10.32B-2.0% | $10.53B-2.7% | ||
| $901M+12.8% | $799M+6.4% | $751M-8.9% | $824M-0.4% | $827M-5.7% | ||
| $9.78B+0.1% | $9.77B+0.7% | $9.71B+0.7% | $9.64B+0.7% | $9.58B+0.7% | ||
| —— | —— | $9.16B-13.1% | $10.54B+42.5% | $7.4B-16.2% | ||
| —— | —— | $15.86B-8.5% | $17.33B+21.3% | $14.29B-9.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pfizer's revenue?
- Pfizer (PFE) generated $63.3B in revenue over the trailing twelve months, up 1.4% year over year.
- Is Pfizer profitable?
- Pfizer reported $12.1B in net income over the trailing twelve months, a 15.7% net margin.
- What is Pfizer's earnings per share?
- Pfizer's diluted EPS over the trailing twelve months is $2.12.
- Where does Pfizer's income statement data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
